GlassScriptPhysician profile
Chandrasekhar Kothuru
NPI 1598287328
$718.02
in general payments reported to CMS, 2019-2025
15 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $135 · 2024: $309 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $220.37 | 2022-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $102.39 | 2022-2024 | |
| Exact Sciences Corporation | $75.68 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $57.18 | 2022-2024 | Wegovy |
| Sumitomo Pharma America, INC. | $44.54 | 2025 | Gemtesa |
| Amgen INC. | $43.92 | 2024 | Repatha, Otezla |
| Dynavax Technologies Corporation | $28.71 | 2024 | Heplisav-B |
| Pfizer INC. | $27.95 | 2022-2023 | |
| Dexcom, INC. | $23.33 | 2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $21.23 | 2024 | Airsupra |
| Xeris Pharmaceuticals, INC. | $17.57 | 2024 | Gvoke Hypopen |
| Cequr Corporation | $15.17 | 2024 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $13.82 | 2023 | Nuedexta |
| Phathom Pharmaceuticals, INC. | $13.35 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandrasekhar Kothuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.